Thus, although the medicine expense for PEG-IFN-α is higher than NA treatment, it could not only strongly inhibits viral replication and reduces HBsAg level, but also eliminates progression to end-stage liver diseases, leading to the down-regulation of both direct and indirect costs as well as potential long-term benefits. The gene discussed is IFNA2; the disease is liver disorder.